Rheumatology (Oxford, England)最新文献

{"title":"SARS-CoV-2 vaccinations in children and adolescents with rheumatic diseases.","authors":"Ethan S Sen, Dalila Julandani, Athimalaipet V Ramanan","doi":"10.1093/rheumatology/keac431","DOIUrl":"https://doi.org/10.1093/rheumatology/keac431","url":null,"abstract":"","PeriodicalId":379078,"journal":{"name":"Rheumatology (Oxford, England)","volume":" ","pages":"4229-4231"},"PeriodicalIF":5.5,"publicationDate":"2022-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384573/pdf/keac431.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40577549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease.","authors":"Xianhua Gui,&nbsp;Shi Shenyun,&nbsp;Hui Ding,&nbsp;Rujia Wang,&nbsp;Jingzhi Tong,&nbsp;Min Yu,&nbsp;Tingting Zhao,&nbsp;Miao Ma,&nbsp;Jingjing Ding,&nbsp;Xiaoyan Xin,&nbsp;Yuying Qiu,&nbsp;Xiaohua Qiu,&nbsp;Yingwei Zhang,&nbsp;Min Cao,&nbsp;Mei Huang,&nbsp;Mengshu Cao,&nbsp;Jinghong Dai,&nbsp;Hourong Cai,&nbsp;Yonglong Xiao","doi":"10.1093/rheumatology/keac090","DOIUrl":"https://doi.org/10.1093/rheumatology/keac090","url":null,"abstract":"<p><strong>Objectives: </strong>In the present study, we aimed to assess the prevalence and clinical significance of anti-Ro52 antibodies in a cohort of patients with idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-ILD) with different myositis-specific autoantibodies (MSAs).</p><p><strong>Methods: </strong>A cohort of 267 IIM-ILD patients, including 62 patients with PM, 126 patients with DM and 79 patients with clinically amyopathic DM (CADM) were retrospectively analysed in this study. Clinical and laboratory findings, pulmonary function tests (PFTs), HRCT patterns and treatment information were compared between patients with and without anti-Ro52 antibodies. The association between prognosis and anti-Ro52 antibodies was also evaluated based on different MSA subgroups.</p><p><strong>Results: </strong>Anti-Ro52 antibodies were more frequent in patients with anti-MDA5 (62.1%, P &lt; 0.01) and anti-Jo1 (64.9%, P &lt; 0.01) antibodies than in those with other MSAs. The proportion of patients with anti-Jo1 antibodies was higher in the anti-Ro52 antibody-positive group than in the anti-Ro52 antibody-negative group. Patients with anti-Ro52 antibodies were more likely to exhibit the Gottron sign than the anti-Ro52 antibody-negative group (P &lt; 0.001). Furthermore, it was a predictive factor for rapid progression interstitial lung disease (RP-ILD) (P = 0.001) and was also associated with a higher mortality rate (log-rank test, P = 0.001). Furthermore, RP-ILD was more frequently exhibited in anti-MDA5- and anti-Ro52-positive patients. Moreover, anti-Ro52 antibody positivity was closely associated with a higher mortality rate in anti-MDA5-ILD patients (log-rank test, P &lt; 0.05).</p><p><strong>Conclusions: </strong>Anti-Ro52 antibodies were highly prevalent in patients with anti-MDA5 and anti-Jo1 antibodies. Within all patients with IIM-ILD, those with anti-Ro52 autoantibodies had a higher frequency of RP-ILD and a poorer prognosis, especially in the anti-MDA5 antibody subgroup.</p>","PeriodicalId":379078,"journal":{"name":"Rheumatology (Oxford, England)","volume":" ","pages":"4570-4578"},"PeriodicalIF":5.5,"publicationDate":"2022-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39910643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis.","authors":"Jacqueline So,&nbsp;Ho So,&nbsp;Victor Tak-Lung Wong,&nbsp;Roy Ho,&nbsp;Tsz Yuen Wu,&nbsp;Priscilla Ching-Han Wong,&nbsp;Lydia Ho-Pui Tam,&nbsp;Chi Ho,&nbsp;Tommy Tsz-On Lam,&nbsp;Yuen Kwan Chung,&nbsp;Wai Ling Li,&nbsp;Chi Hung To,&nbsp;Chak Sing Lau,&nbsp;Chi Chiu Mok,&nbsp;Lai-Shan Tam","doi":"10.1093/rheumatology/keac094","DOIUrl":"https://doi.org/10.1093/rheumatology/keac094","url":null,"abstract":"<p><strong>Objective: </strong>Anti-melanoma differentiation-associated protein 5 (MDA5)-positive DM is associated with rapidly progressive interstitial lung disease (RP-ILD) and high mortality. This multicentre retrospective study aimed to identify predictors of mortality and RP-ILD.</p><p><strong>Methods: </strong>Anti-MDA5-positive DM patients were identified from the Hong Kong Myositis Registry and the Clinical Data Analysis and Reporting System. Clinical characteristics were reviewed. Risk factors for mortality and RP-ILD were identified.</p><p><strong>Results: </strong>Among the 116 recruited patients, 100 (86.2%) had ILD, 47 (40.5%) had RP-ILD and 44 (37.9%) patients died. Cox regression analysis revealed RP-ILD [hazard ratio (HR) 9.735 (95% CI 3.905, 24.272)], age &gt;52 years [HR 4.750 (95% CI 1.692, 13.333)], ferritin level &gt;2800 pmol/l [HR 3.042 (95% CI 1.323, 6.997)] and lactate dehydrogenase (LDH) &gt;400 IU/l [HR 2.290 (95% CI 1.009, 5.198)] were independent predictors of mortality. With regard to RP-ILD, analyses showed that potential predictors at baseline included age &gt;50 years [HR 2.640 (95% CI 1.277, 5.455)], LDH &gt;300 IU/l [HR 3.189 (95% CI 1.469, 6.918)], fever [HR 1.903 (95% CI 0.956, 3.790)] and neutrophil:lymphocyte ratio &gt;7.0 [HR 1.967 (95% CI 0.942, 4.107)]. We proposed a prediction model based on fever, LDH, age and white cell count (FLAW) to stratify the risk of development of RP-ILD. The probability of RP-ILD in a patient with a score of 4 was 100%. A small internal validation cohort showed the odds of RP-ILD with FLAW scores of 0, 1, 2 and 3 were 0%, 0%, 42.9% and 75%, respectively.</p><p><strong>Conclusions: </strong>Anti-MDA5-associated RP-ILD is significantly associated with poor survival rates. The FLAW model maybe useful to predict the development of RP-ILD.</p>","PeriodicalId":379078,"journal":{"name":"Rheumatology (Oxford, England)","volume":" ","pages":"4437-4444"},"PeriodicalIF":5.5,"publicationDate":"2022-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39917027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IL-25 participates in keratinocyte-driven dermal matrix turnover and is reduced in systemic sclerosis epidermis.","authors":"Barbara Russo,&nbsp;Julia Borowczyk,&nbsp;Pietro Cacialli,&nbsp;Philippe Moguelet,&nbsp;Marie-Elise Truchetet,&nbsp;Ali Modarressi,&nbsp;Nicolò C Brembilla,&nbsp;Julien Bertrand,&nbsp;Wolf-Henning Boehncke,&nbsp;Carlo Chizzolini","doi":"10.1093/rheumatology/keac044","DOIUrl":"https://doi.org/10.1093/rheumatology/keac044","url":null,"abstract":"<p><strong>Objectives: </strong>Evidence shows that dysfunctional SSc keratinocytes contribute to fibrosis by altering dermal homeostasis. Whether IL-25, an IL-17 family member regulating many epidermal functions, takes part in skin fibrosis is unknown. Here we address the role of IL-25 in skin fibrosis.</p><p><strong>Methods: </strong>The expression of IL-25 was evaluated by immunofluorescence and in situ hybridization in 10 SSc and seven healthy donor (HD) skin biopsies. Epidermal equivalents (EE) reconstituted by primary HD keratinocytes were used as a model to study transcriptomic changes induced by IL-25 in the epidermis. RNA expression profile in EEs was characterized by RNAseq. The conditioned medium (CM) from primary SSc and HD keratinocytes primed with IL-25 was used to stimulate fibroblasts. IL-6, IL-8, MMP-1, type-I collagen (Col-I), and fibronectin production by fibroblasts was assessed by ELISA.</p><p><strong>Results: </strong>SSc epidermis expressed lower levels of IL-25 compared with HDs. In EEs, IL-25 regulated several molecular pathways related to wound healing and extracellular matrix remodelling. Compared with control CM, the CM from IL-25-primed keratinocytes enhanced the fibroblast production of MMP-1, IL-6 and IL-8, but not of Col-I nor fibronectin. However, IL-25 significantly reduced the production of Col-I when applied directly to fibroblasts. The activation of keratinocytes by IL-25 was receptor-dependent and evident after a very short incubation time (10 min), largely mediated by IL-1, suggesting enhanced and specific release of preformed mediators.</p><p><strong>Conclusions: </strong>These results show that IL-25 participates in skin homeostasis, and its decreased expression in SSc may contribute to skin fibrosis by favouring extracellular matrix deposition over degradation.</p>","PeriodicalId":379078,"journal":{"name":"Rheumatology (Oxford, England)","volume":" ","pages":"4558-4569"},"PeriodicalIF":5.5,"publicationDate":"2022-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39928743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clonal haematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study).","authors":"Clémence David,&nbsp;Nicolas Duployez,&nbsp;Philippine Eloy,&nbsp;Drifa Belhadi,&nbsp;Julie Chezel,&nbsp;Véronique Le Guern,&nbsp;Cédric Laouénan,&nbsp;Laurène Fenwarth,&nbsp;Diane Rouzaud,&nbsp;Alexis Mathian,&nbsp;Sébastien de Almeida Chaves,&nbsp;Pierre Duhaut,&nbsp;Olivier Fain,&nbsp;Lionel Galicier,&nbsp;Pascale Ghillani-Dalbin,&nbsp;Jean Emmanuel Kahn,&nbsp;Nathalie Morel,&nbsp;Laurent Perard,&nbsp;Micheline Pha,&nbsp;Francoise Sarrot-Reynauld,&nbsp;Olivier Aumaitre,&nbsp;François Chasset,&nbsp;Nicolas Limal,&nbsp;Helene Desmurs-Clavel,&nbsp;Felix Ackermann,&nbsp;Zahir Amoura,&nbsp;Thomas Papo,&nbsp;Claude Preudhomme,&nbsp;Nathalie Costedoat-Chalumeau,&nbsp;Karim Sacre","doi":"10.1093/rheumatology/keac108","DOIUrl":"https://doi.org/10.1093/rheumatology/keac108","url":null,"abstract":"<p><strong>Objective: </strong>The detection of somatic mutations among the genes of myeloid cells in asymptomatic patients-defining clonal haematopoiesis of indeterminate potential (CHIP)-is associated with a predisposition to cardiovascular events (CVEs) in the general population. We aimed to determine whether CHIP was associated with CVEs in SLE patients.</p><p><strong>Methods: </strong>The study is an ancillary study of the randomized, double-blind, placebo-controlled, multicentre PLUS trial conducted from June 2007 through August 2010 at 37 centres in France, involving 573 SLE patients. The search for somatic mutations by high-throughput sequencing of 53 genes involved in clonal haematopoiesis was performed on genomic DNA collected at PLUS inclusion. CHIP prevalence was assessed in SLE and in a retrospective cohort of 479 patients free of haematological malignancy. The primary outcome was an incident CVE in SLE.</p><p><strong>Results: </strong>Screening for CHIP was performed in 438 SLE patients [38 (29-47) years, 91.8% female]. Overall, 63 somatic mutations were identified in 47 patients, defining a CHIP prevalence of 10.7% in SLE. Most SLE patients (78.7%) carried a single mutation. Most variants (62.5%) were located in the DNMT3A gene. CHIP frequency was related to age and to age at SLE diagnosis, and was associated with a lower frequency of aPLs. CHIP occurred &gt;20 years earlier (P &lt; 0.00001) in SLE than in controls. The detection of CHIP at inclusion was not found to be associated with occurrence of CVEs during follow-up [HR = 0.42 (0.06-3.21), P = 0.406].</p><p><strong>Conclusion: </strong>The prevalence of CHIP is relatively high in SLE for a given age, but was not found to be associated with incident CVEs.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, https://clinicaltrials.gov, NCT05146414.</p>","PeriodicalId":379078,"journal":{"name":"Rheumatology (Oxford, England)","volume":" ","pages":"4355-4363"},"PeriodicalIF":5.5,"publicationDate":"2022-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39932574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging.","authors":"Walter P Maksymowych,&nbsp;Rebecca Bolce,&nbsp;Gaia Gallo,&nbsp;Emily Seem,&nbsp;Vladimir J Geneus,&nbsp;David M Sandoval,&nbsp;Mikkel Østergaard,&nbsp;Kurisu Tada,&nbsp;Xenofon Baraliakos,&nbsp;Atul Deodhar,&nbsp;Lianne S Gensler","doi":"10.1093/rheumatology/keac104","DOIUrl":"https://doi.org/10.1093/rheumatology/keac104","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate response rates at week 16 with ixekizumab in patients with radiographic axial SpA (r-axSpA) and elevated or normal/low baseline inflammation measured by serum CRP or spinal MRI using data from two randomized, double-blind, placebo (PBO)-controlled phase III trials.</p><p><strong>Methods: </strong>Biologic-naïve (COAST-V) or TNF inhibitor-experienced (COAST-W) adults with active r-axSpA received 80 mg ixekizumab every 2 weeks (IXEQ2W) or 4 weeks (IXEQ4W) or PBO or active reference [40 mg adalimumab every 2 weeks (ADAQ2W) in COAST-V. At week 16, patients receiving ixekizumab continued as assigned and patients receiving PBO or ADA were rerandomized 1:1 to IXEQ2W or IXEQ4W through week 52. Assessment of SpondyloArthritis international Society 40% (ASAS40) response rates were examined by baseline CRP (≤5 or &gt;5 mg/l) and Spondyloarthritis Research Consortium of Canada (SPARCC) MRI spine inflammation score (&lt;2 or ≥2).</p><p><strong>Results: </strong>In the COAST-V/W integrated dataset (N = 567), significantly more patients treated with ixekizumab achieved ASAS40 response at week 16 by CRP ≤5 mg/l (27% IXEQ4W, P &lt; 0.05; 35% IXEQ2W, P &lt; 0.01 vs 12% PBO), CRP &gt;5 mg/l (39% IXEQ4W, P &lt; 0.001; 43% IXEQ2W, P &lt; 0.001 vs 17% PBO), SPARCC MRI spine score &lt;2 (40% IXEQ4W P &lt; 0.01, 52% IXEQ2W P &lt; 0.001 vs 16% PBO), and SPARCC MRI spine score ≥2 (44% IXEQ4W P &lt; 0.001, 47% IXEQ2W P &lt; 0.001 vs 19% PBO). ASAS40 response was observed with CRP ≤5 mg/l and SPARCC MRI spine score &lt;2 with IXEQ4W (29%) and was significant with IXEQ2W (48%; P &lt; 0.05) vs PBO (13%).</p><p><strong>Conclusion: </strong>Ixekizumab demonstrated efficacy in the treatment of AS/r-axSpA in patients with and without elevated CRP or evidence of spinal inflammation on MRI.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov (https://clinicaltrials.gov): NCT02696785, NCT02696798.</p>","PeriodicalId":379078,"journal":{"name":"Rheumatology (Oxford, England)","volume":" ","pages":"4324-4334"},"PeriodicalIF":5.5,"publicationDate":"2022-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/38/5d/keac104.PMC9629340.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39637874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of sST2 in connective tissue disease patients with pulmonary hypertension.","authors":"Huangshu Ye,&nbsp;Qianwen Wu,&nbsp;Ning Zhang,&nbsp;Jing Shi,&nbsp;Haifeng Zhang,&nbsp;Qiang Wang,&nbsp;Miaojia Zhang,&nbsp;Xiaoxuan Sun","doi":"10.1093/rheumatology/keac055","DOIUrl":"https://doi.org/10.1093/rheumatology/keac055","url":null,"abstract":"<p><strong>Objectives: </strong>Pulmonary arterial hypertension (PAH) is a severe complication of CTD, being one of the leading causes of mortality for patients with this condition. Soluble suppression of tumorigenicity 2 (sST2) is a novel biomarker associated with adverse clinical outcomes in cardiovascular patients. In this study, we investigated the role of sST2 as a predictor of poor clinical outcome in patients with CTD associated with pulmonary hypertension (CTD-PH).</p><p><strong>Methods: </strong>This retrospective cohort study enrolled 71 CTD-PH patients diagnosed by echocardiography. Twenty-one CTD patients without PH were selected for a control group. A receiver operating characteristic (ROC) curve assessed the predictive value of sST2 in assessing 3-year clinical worsening. Hazard ratios associated with potential predictors of clinical worsening were estimated using Cox proportional hazard models. The primary end point was clinical worsening.</p><p><strong>Results: </strong>The level of sST2 was significantly elevated in CTD-PH patients compared with the control group. After a mean follow-up of 25.29 (1.88) months, end point events occurred in 26 patients. sST2 was an independent predictor of clinical worsening and all-cause death in patients with CTD-PH. sST2 ≥ 39.99 ng/ml discriminated 3-year clinical worsening with a sensitivity and specificity of 100% and 84.9%, respectively. The patients with both higher levels of sST2 (≥39.99 ng/ml) and N-terminal pro-brain natriuretic peptide (NT-proBNP) (≥300 ng/l) had the worst prognosis.</p><p><strong>Conclusion: </strong>sST2 ≥ 39.99 ng/ml predicts higher incidence of clinical worsening events in CTD-PH patients. Furthermore, patients with elevated sST2 had significantly worse prognosis among those with high NT-proBNP.</p>","PeriodicalId":379078,"journal":{"name":"Rheumatology (Oxford, England)","volume":" ","pages":"3989-3996"},"PeriodicalIF":5.5,"publicationDate":"2022-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39570831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound findings of calcium pyrophosphate deposition disease at metacarpophalangeal joints.","authors":"Edoardo Cipolletta,&nbsp;Andrea Di Matteo,&nbsp;Gianluca Smerilli,&nbsp;Marco Di Carlo,&nbsp;Jacopo Di Battista,&nbsp;Abhishek Abhishek,&nbsp;Walter Grassi,&nbsp;Emilio Filippucci","doi":"10.1093/rheumatology/keac063","DOIUrl":"https://doi.org/10.1093/rheumatology/keac063","url":null,"abstract":"<p><strong>Objective: </strong>To explore the spectrum of articular and peri-articular ultrasound (US) findings at metacarpophalangeal (MCP) joints in calcium pyrophosphate (CPP) deposition disease (CPPD).</p><p><strong>Methods: </strong>Consecutive CPPD patients (chronic CPP crystal inflammatory arthritis or OA with CPPD), and age- and sex-matched controls with RA were prospectively enrolled. Patients underwent bilateral US examination of MCP joints. CPP deposits, synovial inflammation, osteophytes, cartilage damage and bone erosions were recorded.</p><p><strong>Results: </strong>Sixty CPPD patients (33, 55.0% with OA with CPPD and 27, 45.0% with chronic CPP crystal inflammatory arthritis) and 40 RA patients were enrolled. CPP deposits were detected in 24 (40.0%) CPPD patients and in 3 (7.5%) RA patients (P <0.01). In CPPD patients, different types of CPP deposits were identified at MCP joints: 17 (28.3%) patients had dorsal capsuloligamentous deposits, 14 (23.3%) intra-cartilaginous deposits, 13 (21.7%) lateral capsuloligamentous deposits, 12 (20.0%) intra-articular deposits, eight (13.3%) double contour sign and five (8.3%) flexor digitorum tendons' deposits. CPPD patients with chronic CPP crystal inflammatory arthritis showed more US findings indicating synovial inflammation and CPP deposits than those with OA with CPPD. Conversely, a higher prevalence of US features indicating structural damage was noted in this latter phenotype. CPP deposits and bone erosions were the US findings with the highest value for diagnosing chronic CPP crystal inflammatory arthritis and RA, respectively.</p><p><strong>Conclusion: </strong>This study provides pictorial evidence of the broad spectrum of US findings indicating CPP deposits at MCP joints in CPPD. Furthermore, we reported different US patterns in different CPPD phenotypes.</p>","PeriodicalId":379078,"journal":{"name":"Rheumatology (Oxford, England)","volume":" ","pages":"3997-4005"},"PeriodicalIF":5.5,"publicationDate":"2022-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39575558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysregulation of the gene signature of effector regulatory T cells in the early phase of systemic sclerosis.","authors":"Satomi Kobayashi,&nbsp;Yasuo Nagafuchi,&nbsp;Mai Okubo,&nbsp;Yusuke Sugimori,&nbsp;Hiroaki Hatano,&nbsp;Saeko Yamada,&nbsp;Masahiro Nakano,&nbsp;Ryochi Yoshida,&nbsp;Yusuke Takeshima,&nbsp;Mineto Ota,&nbsp;Yumi Tsuchida,&nbsp;Yukiko Iwasaki,&nbsp;Keigo Setoguchi,&nbsp;Kanae Kubo,&nbsp;Tomohisa Okamura,&nbsp;Kazuhiko Yamamoto,&nbsp;Hirofumi Shoda,&nbsp;Keishi Fujio","doi":"10.1093/rheumatology/keac031","DOIUrl":"https://doi.org/10.1093/rheumatology/keac031","url":null,"abstract":"<p><strong>Objectives: </strong>We evaluated flow-cytometric and transcriptome features of peripheral blood immune cells from early-phase (disease duration <5 years) SSc in comparison with late-phase SSc.</p><p><strong>Methods: </strong>Fifty Japanese patients with SSc (12 early SSc cases and 38 late SSc cases) and 50 age- and sex-matched healthy controls were enrolled. A comparison of flow-cytometric subset proportions and RNA-sequencing of 24 peripheral blood immune cell subsets was performed. We evaluated differentially expressed genes (DEGs), characterized the co-expressed gene modules, and estimated the composition of subpopulations by deconvolution based on single-cell RNA-sequencing data. As a disease control, idiopathic inflammatory myositis (IIM) patients were also evaluated.</p><p><strong>Results: </strong>Analysing the data from early and late SSc, fraction II effector regulatory T cell (Fr. II eTreg) genes showed a remarkable differential gene expression, enriched for genes related to oxidative phosphorylation. Although the flow-cytometric proportion of Fr. II eTregs was not changed in early SSc, deconvolution indicated expansion of the activated subpopulation. Co-expressed gene modules of Fr. II eTregs demonstrated enrichment of the DEGs of early SSc and correlation with the proportion of the activated subpopulation. These results suggested that DEGs in Fr. II eTregs from patients with early SSc were closely associated with the increased proportion of the activated subpopulation. Similar dysregulation of Fr. II eTregs was also observed in data from patients with early IIM.</p><p><strong>Conclusions: </strong>RNA-seq of immune cells indicated the dysregulation of Fr. II eTregs in early SSc with increased proportion of the activated subpopulation.</p>","PeriodicalId":379078,"journal":{"name":"Rheumatology (Oxford, England)","volume":" ","pages":"4163-4174"},"PeriodicalIF":5.5,"publicationDate":"2022-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39691346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of foot health in people with inflammatory arthritis: British Society for Rheumatology guideline scope.","authors":"Lara S Chapman,&nbsp;Michael Backhouse,&nbsp;Lindsay Bearne,&nbsp;Lindsey Cherry,&nbsp;Gavin Cleary,&nbsp;Jasmine Davey,&nbsp;Rachel Ferguson,&nbsp;Adele Grieve,&nbsp;Philip Helliwell,&nbsp;Adam Lomax,&nbsp;Helen McKeeman,&nbsp;Alan Rawlings,&nbsp;Robin Rees,&nbsp;Robbie Rooney,&nbsp;Sarah Ryan,&nbsp;Lucy Sanders,&nbsp;Heidi J Siddle,&nbsp;Sue Varley,&nbsp;Louise Warburton,&nbsp;Jim Woodburn,&nbsp;Edward Roddy","doi":"10.1093/rheumatology/keac340","DOIUrl":"https://doi.org/10.1093/rheumatology/keac340","url":null,"abstract":"The guideline will be developed using the methods and processes outlined in Creating Clinical Guidelines: Our Protocol [1]. This development process to produce guidance, advice and recommendations for practice has","PeriodicalId":379078,"journal":{"name":"Rheumatology (Oxford, England)","volume":" ","pages":"3907-3911"},"PeriodicalIF":5.5,"publicationDate":"2022-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/96/f2/keac340.PMC9536780.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40550188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}